You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Novartis’ remibrutinib shows promise for patients with CSU

Novartis has shared positive top-line results from two late-stage studies analysing remibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, among patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.